Lipum recently announced that the first patient with rheumatoid arthritis has been included and dosed in ongoing phase I clinical trial with SOL-116 in the Netherlands. Previously, only healthy subjects were included in the study, but now the first patient has received a dose of SOL-116 or placebo. To find out more, we contacted Lipum's Clinical Project Leader, Agneta Wennerholm, who is involved in the design and project management of the study.